Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

December 28, 2022

Study Completion Date

December 28, 2022

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

EN001

"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"

DRUG

EN001

"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ENCell

INDUSTRY